{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:55:42Z","timestamp":1790668542162,"version":"4.1.0"},"reference-count":58,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/13696998.2026.2732644","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:08:36Z","timestamp":1790665716000},"page":"2386-2405","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of Orca-T vs allo-HCT with conventional GVHD prophylaxis for the treatment of advanced hematologic malignancies in the United States"],"prefix":"10.1080","volume":"29","author":[{"given":"Rawan","family":"Faramand","sequence":"first","affiliation":[{"name":"Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center","place":["Tampa, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Scott","family":"McClellan","sequence":"additional","affiliation":[{"name":"Orca Bio","place":["Menlo Park, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pavlova","sequence":"additional","affiliation":[{"name":"Orca Bio","place":["Menlo Park, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Manghani","sequence":"additional","affiliation":[{"name":"Orca Bio","place":["Menlo Park, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Blank","sequence":"additional","affiliation":[{"name":"Orca Bio","place":["Menlo Park, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matia","family":"Saeedian","sequence":"additional","affiliation":[{"name":"BluePath Solutions","place":["Los Angeles, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Yadav","sequence":"additional","affiliation":[{"name":"BluePath Solutions","place":["Los Angeles, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[{"name":"Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center","place":["New York, USA"]},{"name":"Department of Medicine, Weill Cornell Medical College","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0047"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007611"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703472"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.06.013"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16203521"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-025-04102-0"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-024-02370-8"},{"key":"e_1_3_5_9_1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/978-3-031-44080-9_26","volume-title":"The EBMT handbook: hematopoietic cell transplantation and cellular therapies","author":"Boelens JJ","year":"2024","unstructured":"Boelens JJ, Bonifazi F, Gj\u00e6rde LK, et al. GVHD Prophylaxis. In: Sureda A, Corbacioglu S, Greco R, et al., editors. The EBMT handbook: hematopoietic cell transplantation and cellular therapies. Cham: Springer International Publishing; 2024. p. 219\u2013227."},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00636"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.05.014"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004846"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-025-03970-w"},{"key":"e_1_3_5_14_1","unstructured":"CIBMTR U.S. Summary Slides GVHD Prophylaxis by Donor Type 2020\u20132023. United States CIBMTR. 2026. https:\/\/cibmtr.org\/CIBMTR\/Resources\/Summary-Slides-Reports"},{"key":"e_1_3_5_15_1","unstructured":"FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients [Internet]. United States U.S. FOOD & DRUG. 2026. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-uses-donor-immune-cells-prevent-serious-complications-blood-cancer."},{"key":"e_1_3_5_16_1","unstructured":"Orca Bio announces positive results from the pivotal Phase 3 study of investigational Orca\u2011T compared to allogeneic stem cell transplant for the treatment of hematologic malignancies. 2025. https:\/\/orcabio.com\/orca-bio-announces-positive-results-from-the-pivotal-phase-3-study-of-investigational-orca-t-compared-to-allogeneic-stem-cell-transplant-for-the-treatment-of-hematologic-malignancies-2\/."},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025031313"},{"key":"e_1_3_5_18_1","unstructured":"Orca Bio DoF. Clinical Study Report Orca Biosystems. Protocol Number Ph3-Precision-T). 2025."},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.04.011"},{"key":"e_1_3_5_20_1","unstructured":"Social Security Administration. Actuarial life table; period life table 2022 as used in the 2025 trustees report. 2025. https:\/\/www.ssa.gov\/oact\/STATS\/table4c6.html"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.10.002"},{"key":"e_1_3_5_22_1","unstructured":"Leiser M. Durable discontinuation of immunosuppressive therapy rare in chronic GVHD 2021. 2026. https:\/\/www.healio.com\/news\/hematology-oncology\/20210210\/durable-discontinuation-of-immunosuppressive-therapy-rare-in-chronic-gvhd"},{"key":"e_1_3_5_23_1","unstructured":"TRENDWATCH CHARTBOOK 2020. 2026. https:\/\/www.aha.org\/system\/files\/media\/file\/2020\/10\/TrendwatchChartbook-2020-Appendix.pdf."},{"key":"e_1_3_5_24_1","unstructured":"Department of Health and Human Services. Centers for Medicare and Medicaid Services. Federal Register\/Vol.89 No. 140\/\/Proposed Rules. 2024. https:\/\/www.federalregister.gov\/documents\/2024\/07\/22\/2024-15087\/medicare-and-medicaid-programs-hospital-outpatient-prospective-payment-and-ambulatory-surgical"},{"key":"e_1_3_5_25_1","unstructured":"US Bureau of Labors Statistics CPI for All Urban Consumers (CPI-U). U.S. city average Medical care - CUUR0000SAM. 2025. https:\/\/www.bls.gov\/cpi\/data.htm"},{"key":"e_1_3_5_26_1","unstructured":"Centers for Medicare and Medicaid Services. Payment Allowance limits for medicare part B drugs. Average selling price 2025. 2026. https:\/\/www.cms.gov\/medicare\/payment\/part-b-drugs\/asp-pricing-files"},{"key":"e_1_3_5_27_1","unstructured":"Kaiser Family Foundation. Hospital adjusted expenses per inpatient day. 2023. https:\/\/www.kff.org\/health-costs\/state-indicator\/expenses-per-inpatient-day\/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22 %22sort%22:%22asc%22%7D"},{"key":"e_1_3_5_28_1","unstructured":"Orca Bio DoF. Orca AlloSCT Donor Procurement Analysis Conducted by BluePath Solutions. 2024."},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05382-4"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx050"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02201-6"},{"key":"e_1_3_5_32_1","unstructured":"Merative Micromedex RED BOOK. 2026. https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/PFDefaultActionId\/redbook.ModifyRedBookSearch"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2020.12.027"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S153286"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.3325\/cmj.2016.57.6"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.12.003"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1344127"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy193"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00170"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.12.945"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014781"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2023.14.6.5"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02293"},{"key":"e_1_3_5_44_1","doi-asserted-by":"crossref","unstructured":"Pasquini Rs MC Logan B Kaur M et al. editor. Calcineurin inhibitor-free Graft-versus-Host Disease (GVHD) prophylaxis in Hematopoietic Cell Transplantation (HCT) with Myeloablative Conditioning Regimens (MAC) and HLA-Matched Donors: long term follow up of BMT CTN 1301 PROGRESS II Trial. Tandem Conference; 2024.","DOI":"10.1016\/j.jtct.2023.12.083"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2215943"},{"key":"e_1_3_5_46_1","unstructured":"EBMT oral presentation 51st Annual Meeting Florence Italy. (30 March - 2 April 2025) - ORCA-T Demonstrates Improved Survival Free of Chronic GvHD Compared to Conventional Allogeneic Hematopoietic Stem Cell Transplant: a Randomized Phase 3 Trial in Advanced Hematologic Malignancies. EBMT; 2025."},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2021.02.011"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2024.04.003"},{"key":"e_1_3_5_49_1","unstructured":"Healthcare Cost and Utilization Project (HCUPnet). 2022. https:\/\/datatools.ahrq.gov\/hcupnet\/"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2023.12.011"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20095743"},{"issue":"11","key":"e_1_3_5_52_1","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1111\/jce.14153","article-title":"Potential cost-effectiveness of wearable cardioverter-defibrillator for patients with implantable cardioverter-defibrillator explant in a high-income city of China","volume":"30","author":"Jiang X","year":"2019","unstructured":"Jiang X, Ming WK, You JHS. Potential cost-effectiveness of wearable cardioverter-defibrillator for patients with implantable cardioverter-defibrillator explant in a high-income city of China. J Cardiovasc Electrophysiol. 2019;30(11):2387\u20132396.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2020.08.008"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-015-0772-9"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.1792"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005847"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008792"},{"key":"e_1_3_5_58_1","unstructured":"Munshi Tw P McCurdy S Nath R et al. editors. ASH 2025 oral presentation american society of hematology. 2025."},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503189"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2732644","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13696998.2026.2732644","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2732644","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:08:46Z","timestamp":1790665726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2026.2732644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/13696998.2026.2732644"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2026.2732644","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-07-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}